Hormonal
The metabolic phenotype caused by adipose NAPE-PLD deletion is mediated by changes in gut microbiota composition, as evidenced by the partial transfer of the obese and insulin-resistant phenotype to germ-free mice via fecal microbiota transplantation.
Your gut bacteria play a direct role in your body weight and insulin sensitivity. This study shows that the specific mix of bacteria in your gut can transmit metabolic health information to your fat tissue. While this is a mouse study, it suggests that supporting a healthy gut microbiome may be an important part of metabolic health strategies.
Our results indicate that these alterations are mediated by a shift in gut microbiota composition that can partially transfer the phenotype to germ-free mice.
Why this rating
Strong evidence using germ-free mouse models and microbiota transfer, a gold standard for establishing causality in microbiome research.
Source
Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota
Lucie Geurts et al. · Nature Communications · 2015
DOI 10.1038/ncomms7495
More from this paper
- Deletion of the endocannabinoid-synthesizing enzyme NAPE-PLD specifically in adipose tissue causes obesity, glucose intolerance, and insulin resistance in mice, primarily through impaired adipose browning and altered gut microbiota composition.Good
- Adipose tissue NAPE-PLD is essential for the browning process of white adipose tissue; its deletion impairs cold-induced thermogenesis and reduces the expression of browning markers like Ucp1 and Ppargc1a.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →